Close Menu

NEW YORK, Nov. 1 — Human Genome Sciences on Thursday announced that a monoclonal antibody product it developed has been approved by the US Food and Drug Administration to begin phase I trials, becoming the first drug candidate of its kind identified through genomics techniques to reach this stage.

The product, LymphoStat-B, will first be tested as a treatment for the autoimmune disease lupus. Clinical trials should begin by the new year, said company spokesperson Jerry Parrot. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.